Related references
Note: Only part of the references are listed.Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?
Larissa Lee et al.
GYNECOLOGIC ONCOLOGY (2019)
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
Hyun Cheol Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Brian I. Rini et al.
LANCET (2019)
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial
R. Wendel Naumann et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Immunotherapy for Uterine Cervical Cancer
Masahiro Kagabu et al.
HEALTHCARE (2019)
Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer
Neal S. McCall et al.
CLINICAL CANCER RESEARCH (2018)
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Kabir A. Khan et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
M. A. Socinski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect
Maria E. Rodriguez-Ruiz et al.
TRENDS IN IMMUNOLOGY (2018)
The relationship between the PD-1/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance
Yang-chun Feng et al.
CANCER MANAGEMENT AND RESEARCH (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
PD-L1 Expression Correlates With Tumor Infiltrating Lymphocytes And Response To Neoadjuvant Chemotherapy In Cervical Cancer
Ying Meng et al.
JOURNAL OF CANCER (2018)
T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection
Jonathan A. Trujillo et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial
Jean-Sebastien Frenel et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer
Emeka K. Enwere et al.
MODERN PATHOLOGY (2017)
Increased expression of PD-L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity
Chaoqi Liu et al.
MOLECULAR MEDICINE REPORTS (2017)
Human papilloma virus load and PD-1/PD-L1, CD8+ and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy
Panagiotis Balermpas et al.
ONCOIMMUNOLOGY (2017)
Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas
Opal L. Reddy et al.
DIAGNOSTIC PATHOLOGY (2017)
Cancer immunotherapies targeting the PD-1 signaling pathway
Yoshiko Iwai et al.
JOURNAL OF BIOMEDICAL SCIENCE (2017)
Systematic review of case reports on the abscopal effect
Yazan Abuodeh et al.
CURRENT PROBLEMS IN CANCER (2016)
Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation
Tomonori Yaguchi et al.
INTERNATIONAL IMMUNOLOGY (2016)
Immune checkpoint inhibition in ovarian cancer
Junzo Hamanishi et al.
INTERNATIONAL IMMUNOLOGY (2016)
Genomics-and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors A Review
Krijn K. Dijkstra et al.
JAMA ONCOLOGY (2016)
Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers
Louisa Mezache et al.
MODERN PATHOLOGY (2015)
Improved Survival with Bevacizumab in Advanced Cervical Cancer
Krishnansu S. Tewari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death
Encouse B. Golden et al.
ONCOIMMUNOLOGY (2014)
Hypoxia promotes tumor growth in linking angiogenesis to immune escape
Salem Chouaib et al.
FRONTIERS IN IMMUNOLOGY (2012)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Share Paper
